Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Emapalumab-behandling for forventet klinisk nytte ved sepsis drevet av interferon-gamma-endotypen (EMBRACE-forsøket) (EMBRACE)

16. november 2026 oppdatert av: Hellenic Institute for the Study of Sepsis

EMBRACE is a double-blind, randomized, placebo-controlled, phase IIa study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to investigate if treatment with emapalumab, a monoclonal antibody which blocks IFNγ, may improve the outcome of patients with sepsis driven by the IDS (endotype of IFNγ-driven sepsis) endotype. EMBRACE also aims to identify the best dosing regimen of emapalumab for the management of IDS.

Studieoversikt

Detaljert beskrivelse

The EMBRACE trial aims to generate proof-of-concept if treatment with emapalumab, a monoclonal antibody which blocks IFNγ signaling, may improve the outcome of patients with sepsis driven by the IDS endotype. In EMBRACE, two different dose regimens of emapalumab are administered in order to: a) investigate which dose regimen may provide most of efficacy in the decrease of SOFA score, a new endpoint for sepsis suggested already by others; b) investigate which dose regimen better attains the pharmacodynamic goal of emapalumab defined as the decrease of blood CXCL9; and c) compare the efficacy of the two dose regimens with placebo treated patients.

Studietype

Intervensjonell

Registrering (Faktiske)

75

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Alexandroupoli, Hellas
        • Intensive Care Unit, Alexandroupolis University General Hospital
      • Athens, Hellas
        • 4th Department of Internal Medicine, ATTIKON University General Hospital
      • Athens, Hellas
        • Intensive Care Unit, Korgialeneio-Benakeio HRC Athens General Hospital
      • Athens, Hellas
        • 3rd University Department of Internal Medicine, Sotiria Chest Diseases Athens General Hospital
      • Athens, Hellas
        • Intensive Care Unit I, KAT Attica General Hospital
      • Athens, Hellas
        • Intensive Care Unit of 1st University Department Respiratory Medicine, Sotiria Chest Diseases Athens General Hospital
      • Athens, Hellas
        • Intensive Care Unit of Center for Respiratory Failure, Sotiria Chest Diseases Athens General Hospital
      • Athens, Hellas
        • Intensive Care Unit, Asklipieio Voulas General Hospital
      • Athens, Hellas
        • Intensive Care Unit, Ippokrateio Athens General Hospital
      • Athens, Hellas
        • Intensive Care Unit, Laiko Athens General Hospital
      • Athens, Hellas
        • New Multivalent Intensive Care Unit, Sotiria Chest Diseases Athens General Hospital
      • Athens, Hellas
        • Ηigh Dependency Unit of Department of Clinical Therapeutics, Alexandra Athens General Hospital
      • Pátrai, Hellas
        • Intensive Care Unit, Patras University General Hospital
      • Thessaloniki, Hellas
        • 1st Intensive Care Unit, G. Papanikolaou Thessaloniki General Hospital
      • Thessaloniki, Hellas
        • Department of Anesthesiology and Intensive Care, AHEPA Thessaloniki University General Hospital
      • Thessaloniki, Hellas
        • Intensive Care Unit, 424 General Military Training Hospital
      • Thessaloniki, Hellas
        • Intensive Care Unit, Aghios Dimitrios Thessaloniki General Hospital
      • Thessaloniki, Hellas
        • Intensive Care Unit, G. Gennimatas Thessaloniki General Hospital
      • Thessaloniki, Hellas
        • Intensive Care Unit, Ippokrateio Thessaloniki General Hospital
      • Thessaloniki, Hellas
        • Intensive Care Unit, Papageorgiou Thessaloniki General Hospital
      • Thessaloniki, Hellas
        • Intensive Care Unit, Theageneio Thessaloniki Cancer Hospital
    • Attica
      • Elefsina, Attica, Hellas
        • 1st Department of Internal Medicine, Thriasio Elefsis General Hospital
      • Kifissia, Attica, Hellas
        • Clinic of Intensive Care and Pulmonary Diseases, Aghioi Anargyroi Kifissia General Oncologic Hospital
    • Crete
      • Heraklion, Crete, Hellas
        • Intensive Care Unit, University General Hospital of Heraklion

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Provide written informed consent
  • Adults (≥18 years) of male or female sex
  • Diagnosis of community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), intrabdominal infection (IAI), acute pyelonephritis (AP), primary bloodstream infection (BSI) and viral respiratory infections.
  • Sepsis defined by the Sepsis-3 definitions. This is defined as any new infection which is accompanied by an increase of the total baseline SOFA score by at least 2 points. The total baseline SOFA score is calculated by the medical comorbidities and by the evaluation of clinical variables before the sepsis episode in the case of hospital-acquired sepsis. In the case of patients with unknown baseline SOFA score, sepsis is defined as any new infection accompanied by total SOFA score 2 or more.
  • Willingness to use effective contraceptive methods during the period from the start of the study drug to 6 months after the administration of the last dose of the study drug, in patients of reproductive age.
  • Serological documentation of IDS defined as detectable blood IFNγ and CXCL9 more than 2,200 pg/ml. IFNγ and CXCL9 are measured in the central study lab by an enzyme immunosorbent assay.
  • Absence of sepsis-induced immunoparalysis (SII). This is defined as ≥8000 of HLA-DR receptors on CD45/CD14-monocytes measured by flow-cytometry in the central lab using the BD™ fluorescence assay9.

Exclusion Criteria:

  • Body weight more than 104 kg
  • Intake of any other biological during the last 30 days prior screening except for the intake of anakinra or tocilizumab for patients with active infection by SARS-CoV-2
  • Intake of any Janus kinase inhibitors during the last 30 days prior screening except for the intake of baricitinib for patients with active infection by SARS-CoV-2
  • Known active infection by Mycobacterium tuberculosis or other mycobacteria. These patients may be enrolled in the trial if treatment against infection by Mycobacterium tuberculosis or other mycobacteria has been initiated
  • Known active infection by VZV (varicella zoster virus) or by Histoplasma capsulatum or by Leishmania spp. These patients may be enrolled in the trial if treatment against infection by VZV or Histoplasma capsulatum has been initiated
  • Known active infection by the hepatitis B virus, by the hepatitis C virus and by cytomegalovirus
  • Vaccination the last 12 weeks before screening with BCG vaccine
  • Vaccination with any live or attenuated live vaccine (other than BCG) the last 12 weeks before screening
  • Known allergy or hypersensitivity reactions to emapalumab
  • Patients living with the human immunodeficiency virus (HIV)
  • Patients with stage IV solid or hematologic malignancy
  • Patients with neutropenia (less than 1,000 neutrophils/mm3)
  • Patients transplanted for solid organ or stem cells
  • Pregnancy or lactation
  • Participation in any other interventional trial the last 28 days prior to day 1

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

Standard-of-care (SoC) treatment and placebo drug.

250ml of 0.9% sodium chloride. The drug is administered on day 0 and repeated dosing is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply

Aktiv komparator: Emapalumab Group 1

SoC treatment and a low dose of emapalumab.

The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.

Andre navn:
  • Emapalumab gruppe 1

The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.

Andre navn:
  • Emapalumab gruppe 2
Aktiv komparator: Emapalumab Group 2

SoC treatment and a high dose of emapalumab.

The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.

Andre navn:
  • Emapalumab gruppe 1

The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.

Andre navn:
  • Emapalumab gruppe 2

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Decrease of SOFA score by the end-of-treatment
Tidsramme: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.

The study primary endpoint is the decrease of SOFA score by the end-of-treatment (EOT). This is defined as either a) at least 1.4 points decrease of mean SOFA score calculated between days 1 and EOT from SOFA score of day 0; OR b) at least 2 points decrease of SOFA at EOT from day 0.

From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Antall doser som kreves i hver gruppe for å oppnå SOFA-score-responsen av EOT.
Tidsramme: Fra påmelding til slutten av behandlingen av studiemedikamentet for hver av studiedeltakerne, fra 2 til 29 dager.
Fra påmelding til slutten av behandlingen av studiemedikamentet for hver av studiedeltakerne, fra 2 til 29 dager.
28 dagers dødelighet
Tidsramme: Fra påmelding til 28 dager etter påmelding.
Fra påmelding til 28 dager etter påmelding.
The rate of serious TEAEs and non-serious TEAEs
Tidsramme: From enrollment to the end of observation of each of the study participants, which is 120 days plus or minus 3 days, after each participant's enrollment.

Comparison of the rate of serious TEAEs and non-serious TEAEs between the three groups of treatment.

From enrollment to the end of observation of each of the study participants, which is 120 days plus or minus 3 days, after each participant's enrollment.
The change of the SOFA score from day 0 until day 7
Tidsramme: From enrollment (day 0) to 8 days after enrollment (day 7).

Comparison of the change of the SOFA score from day 0 until day 7

From enrollment (day 0) to 8 days after enrollment (day 7).
The change of the SOFA score from 0 until day 28
Tidsramme: From enrollment to 28 days after enrollment.

Comparison of the change of the SOFA score from 0 until day 28

From enrollment to 28 days after enrollment.
The change of the SOFA score from 0 until EOT
Tidsramme: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.

Comparison of the change of the SOFA score from 0 until EOT

From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
The pharmacokinetics of emapalumab
Tidsramme: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.

Comparison of the pharmacokinetics of emapalumab

From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
The need to stop the study drug due to drop of the number of HLA-DR receptors on CD14-monocytes.
Tidsramme: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.

Comparison of the need to stop the study drug due to drop of the number of HLA-DR receptors on CD14-monocytes.

From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
The circulating concentrations of IL-6, ferritin, IFNγ and CXCL9 over the days of treatment
Tidsramme: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.

Comparison of the circulating concentrations of IL-6, ferritin, IFNγ and CXCL9 over the days of treatment

From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.

Andre resultatmål

Resultatmål
Tidsramme
Sammenligning mellom de tre gruppene av behandling for den proteomiske profilen over behandling
Tidsramme: Fra påmelding til slutten av behandlingen av studiemedikamentet for hver av studiedeltakerne, fra 2 til 29 dager.
Fra påmelding til slutten av behandlingen av studiemedikamentet for hver av studiedeltakerne, fra 2 til 29 dager.
Sammenligningene mellom de tre behandlingsgruppene for endring av den transkriptomiske profilen over behandling
Tidsramme: Fra påmelding til slutten av behandlingen av studiemedikamentet for hver av studiedeltakerne, fra 2 til 29 dager.
Fra påmelding til slutten av behandlingen av studiemedikamentet for hver av studiedeltakerne, fra 2 til 29 dager.
Den diagnostiske ytelsen til Point-of-care SepsisLoop for SII sammenlignet med det absolutte antallet HLA-DR-reseptorer på CD45/CD14-monocytter.
Tidsramme: Fra påmelding til slutten av behandlingen av studiemedikamentet for hver av studiedeltakerne, fra 2 til 29 dager.
Fra påmelding til slutten av behandlingen av studiemedikamentet for hver av studiedeltakerne, fra 2 til 29 dager.
De kliniske dataene og biomarkørnivåene ved sengen ved screening for potensiell utvikling av et diagnostisk verktøy som klassifiserer studiepopulasjonen i IDS
Tidsramme: Fra påmelding til slutten av behandlingen av studiemedikamentet for hver av studiedeltakerne, fra 2 til 29 dager.
Fra påmelding til slutten av behandlingen av studiemedikamentet for hver av studiedeltakerne, fra 2 til 29 dager.
De prognostiske biomarkørnivåene ved screening klassifiserer sepsis-populasjonen i forskjellige undergrupper
Tidsramme: Fra påmelding til slutten av behandlingen av studiemedikamentet for hver av studiedeltakerne, fra 2 til 29 dager.
Fra påmelding til slutten av behandlingen av studiemedikamentet for hver av studiedeltakerne, fra 2 til 29 dager.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studiestol: Evangelos Giamarellos-Bourboulis, Hellenic Institute for the Studies of Sepsis

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

14. mars 2025

Primær fullføring (Faktiske)

13. mars 2026

Studiet fullført (Faktiske)

14. september 2026

Datoer for studieregistrering

Først innsendt

13. november 2024

Først innsendt som oppfylte QC-kriteriene

15. november 2024

Først lagt ut (Faktiske)

19. november 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. mars 2025

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere